中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
18期
41-43
,共3页
替吉奥%奥沙利铂%老年%胃癌
替吉奧%奧沙利鉑%老年%胃癌
체길오%오사리박%노년%위암
Compound tegafur capsule%Oxaliplatin%Elder%Gastric carcinoma
目的 观察替吉奥胶囊单药与替吉奥联合奥沙利铂治疗老年进展期胃癌的近期疗效、临床受益率和不良反应.方法 48例老年进展期胃癌患者被随机分为观察组和对照组.观察组24例,患者接受替吉奥胶囊单药口服,连用28 d,停药14 d后再进行下1个周期治疗,共完成4个周期化疗；对照组采用替吉奥胶囊口服,连用14 d,服药第1天给予奥沙利铂静脉滴注化疗,休息7d后再进行下1个周期治疗,用药4个周期后评价疗效.结果 观察组总有效率为45.8％,临床受益率为91.7％；对照组总有效率为58.3％,临床受益率为66.7％.两组近期疗效比较差异无统计学意义(P＞0.05),临床受益率、不良反应的发生率组间比较差异有统计学意义(P＜0.05).结论 替吉奥胶囊单药口服治疗老年进展期胃癌可取得较好的近期疗效,可以提高生存质量,耐受性良好.
目的 觀察替吉奧膠囊單藥與替吉奧聯閤奧沙利鉑治療老年進展期胃癌的近期療效、臨床受益率和不良反應.方法 48例老年進展期胃癌患者被隨機分為觀察組和對照組.觀察組24例,患者接受替吉奧膠囊單藥口服,連用28 d,停藥14 d後再進行下1箇週期治療,共完成4箇週期化療；對照組採用替吉奧膠囊口服,連用14 d,服藥第1天給予奧沙利鉑靜脈滴註化療,休息7d後再進行下1箇週期治療,用藥4箇週期後評價療效.結果 觀察組總有效率為45.8％,臨床受益率為91.7％；對照組總有效率為58.3％,臨床受益率為66.7％.兩組近期療效比較差異無統計學意義(P＞0.05),臨床受益率、不良反應的髮生率組間比較差異有統計學意義(P＜0.05).結論 替吉奧膠囊單藥口服治療老年進展期胃癌可取得較好的近期療效,可以提高生存質量,耐受性良好.
목적 관찰체길오효낭단약여체길오연합오사리박치료노년진전기위암적근기료효、림상수익솔화불량반응.방법 48례노년진전기위암환자피수궤분위관찰조화대조조.관찰조24례,환자접수체길오효낭단약구복,련용28 d,정약14 d후재진행하1개주기치료,공완성4개주기화료；대조조채용체길오효낭구복,련용14 d,복약제1천급여오사리박정맥적주화료,휴식7d후재진행하1개주기치료,용약4개주기후평개료효.결과 관찰조총유효솔위45.8％,림상수익솔위91.7％；대조조총유효솔위58.3％,림상수익솔위66.7％.량조근기료효비교차이무통계학의의(P＞0.05),림상수익솔、불량반응적발생솔조간비교차이유통계학의의(P＜0.05).결론 체길오효낭단약구복치료노년진전기위암가취득교호적근기료효,가이제고생존질량,내수성량호.
Objective To evaluate the clinical efficacy,the clinical benefit response(CBR) and adverse reactions of the compound tegafur capsule and compound tegafur capsule combined with oxaliplatin in the treatment of old patients with advanced gastric cancer.Methods Forty - eight old patients with advanced gastric cancer were divided into trial group and control group.In the trail group ( n =24),compound tegafur was administered orally twice daily from d1 to d28,42 days for a cycle and continuous for 4 cycles.In the control group ( n =24 ),compound tegafur capsule was administered orally twice daily from dl to d14,and intravenous of oxaliplatin was administered in first day,21 days for a cycle and continuous for 4 cycles.We assessed efficacy,the clinical benefit response(CBR) and toxicity after chemotherapy.Results All of the 48 patients could be evaluated for clinical response,the clinical benefit response(CBR) and toxicity.The total response rate in trial group was 45.8％ and 58.3％ in control group,there were no difference between the two groups.The clinical benefit response in trial group was 91.7％ and 66.7％ in control group,there were significant difference between the two groups.There were significant difference in partial adverse reactions between the two groups.Conclusions The compound tegafur capsule has shown activity for old patients in treatment of advanced gastric cancer(AGC),and it is well -tolerated.
